# DESCRIPTION

## 1. INTRODUCTION

- introduce ATRX biomarker

## 2. BACKGROUND OF THE INVENTION

- motivate CDK4 inhibition therapies
- describe limitations of CDK4 therapies
- introduce ATRX gene function

## 3. SUMMARY OF THE INVENTION

- summarize invention scope

## 5. DETAILED DESCRIPTION OF THE INVENTION

- introduce ATRX as biomarker

### 5.1 ATRX as a Biomarker

- define ATRX
- specify human ATRX protein
- specify mouse ATRX protein
- specify rat ATRX protein
- describe ATRX biomarker detection
- define Responder Cell
- define Non-responder Cell
- describe ATRX biomarker in Responder Cells
- describe ATRX biomarker in Non-responder Cells
- specify post-translationally modified ATRX biomarker
- define detectable ATRX biomarker
- define undetectable ATRX biomarker
- describe immunoblot detection
- list cell lines with detectable ATRX
- list cell lines with undetectable ATRX
- describe reference control level of ATRX
- list methods for detecting ATRX
- describe Western blotting method
- describe immunohistochemistry method

### 5.2 Anti-ATRX Antibodies

- define antibody
- motivate ATRX antibodies
- describe antibody types
- introduce anti-ATRX antibodies
- describe antibody specificity
- exemplify anti-ATRX antibodies
- describe epitope binding
- specify ATRX epitope regions
- describe phosphorylated ATRX binding
- describe dimethylated ATRX binding
- describe acetylated ATRX binding
- describe antibody generation
- describe immunization methods
- describe antibody production
- describe polyclonal antibody production
- describe monoclonal antibody production
- describe antibody testing
- describe ELISA testing
- describe Western blot testing
- describe competition assays
- describe antibody fragments
- describe Fab fragments
- describe F(ab')2 fragments
- describe Fv fragments
- describe scFv fragments
- describe chimeric antibodies
- describe humanized antibodies
- describe human framework regions
- describe human antibody production
- describe transgenic animal production
- describe hybridoma-based methods
- describe phage display libraries
- describe labeled antibodies
- describe direct detection labels
- describe indirect detection labels
- describe enzyme-linked labels
- describe biotin/avidin labels
- describe spin labels
- describe bacteriophage labels

### 5.3 CDK4 Inhibitors

- introduce CDK4 inhibitors
- describe ATP-competitive inhibitors
- exemplify CDK4 inhibitors

### 5.4 Cancer Targets

- list cancer examples

### 5.5 Methods of Use

- define anti-cancer effect
- specify non-human subjects
- describe sample types
- define ATRX biomarker detection
- specify ATRX protein detection
- describe CDK4 inhibitor treatment
- define therapeutically effective amount
- introduce therapeutic methods using Bethyl antibody
- describe ATRX biomarker detection using '045 Ab
- specify ATRX biomarker detection in cancer cells
- describe ATRX biomarker detection in non-responders
- introduce method for producing anti-cancer effect
- describe ATRX biomarker detection before treatment
- specify CDK4 inhibitor treatment after ATRX detection
- describe ATRX biomarker detection after treatment
- specify CDK4 inhibitor treatment after ATRX detection post-treatment
- describe CDK4 inhibitor treatment options
- introduce therapeutic methods using ATRX antibodies of section 5.2
- describe ATRX biomarker detection using Ab3, Ab4, Ab5, or Ab10
- specify ATRX phosphorylation detection
- describe ATRX symmetric methylation detection
- specify ATRX antibody specificity
- introduce method for determining anti-cancer effect
- describe ATRX biomarker detection before treatment using Ab3, Ab4, Ab5, or Ab10
- specify alternative treatment options
- describe ATM, ATR, and DNA-PK inhibitors
- specify non-limiting examples of inhibitors
- provide references for additional inhibitors
- introduce methods of use
- obtain cancer sample before treatment
- determine ATRX biomarker level
- initiate treatment with CDK4 inhibitor
- obtain cancer sample after treatment
- determine ATRX biomarker level
- initiate treatment with alternative modality
- collect sample before and after treatment
- monitor and/or compare ATRX levels
- define "in combination with"
- collect cancer cell sample
- introduce therapeutic methods using ATRX P-S2487 biomarker
- determine ATRX P-S2487 biomarker level
- predict anti-cancer effect of CDK4 inhibitor
- obtain cancer sample before treatment
- determine ATRX P-S2487 biomarker level
- initiate treatment with alternative modality
- obtain cancer sample after treatment
- determine ATRX P-S2487 biomarker level
- initiate treatment with alternative modality
- collect sample before and after treatment
- monitor and/or compare ATRX levels
- introduce assay for identifying modalities
- treat cells with CDK4 inhibitor
- treat cells with second modality
- determine number of ATRX foci per cell
- screen for candidate compounds
- identify compounds that increase ATRX foci
- determine number of ATRX foci per cell
- compare to reference standard
- use immunohistochemistry to detect ATRX foci
- score ATRX foci visually
- quantitate results
- treat cancer cells with CDK4 inhibitor
- determine number of ATRX foci per cell

### 5.6 Kits

- introduce kit for determining anti-cancer effect
- list types of kits
- describe kit for detecting protein levels
- specify antibodies for immunodetection
- describe detectable labels for immunodetection
- provide solid support for antibody
- specify kit components for biomarker detection
- include instructions for using kit

## 6. EXAMPLE 1

### 6.1 Materials and Methods

- describe immunoblot protocol
- describe immunofluorescence protocol
- detail cell harvesting and lysis
- outline protein resolution and transfer

### 6.2 Results

- introduce senescence as favorable clinical outcome
- describe ALT in soft tissue sarcomas
- measure ALT in responder and non-responder cell lines
- analyze ATRX protein expression
- correlate ATRX expression with ALT phenotype
- genetically manipulate ATRX expression
- measure SA-Î²-gal accumulation
- analyze MDM2 protein turnover
- discuss ATRX role in senescence pathway

### 6.3 Discussion

- summarize ATRX importance in senescence program
- propose ATRX mechanism in MDM2 turnover
- discuss ATRX/DAXX role in histone H3.3 deposition
- compare histone chaperone pathways
- suggest ATRX/DAXX significance in senescence pathway

## 7. EXAMPLE 2

### Modified Form of ATRX in Non-Responder Cells

- introduce D5 antibody for ATRX detection
- compare ATRX detection with D5 and Bethyl antibodies
- generate peptides with post-translational modifications
- test peptide reactivity with Bethyl antibody
- perform mass spectrometry to identify modified ATRX form

## 8. EXAMPLE 3

### ATRX Foci in Response to CDK4 Inhibition

- introduce ATRX foci in response to CDK4 inhibition
- describe immunofluorescence analysis
- show increase in ATRX foci in responder cells
- analyze ATRX foci in responder cells undergoing senescence
- determine ATRX foci as a marker for senescence

### 9. EXAMPLE 4

- generate anti-ATRX antibodies
- describe immunization and boosting of mice

### 10. REFERENCES

- list Banumathy et al. reference
- list Clynes et al. reference
- list Drane et al. reference
- list Eustermann et al. reference
- list Goldberg et al. reference
- list Heaphy et al. reference
- list multiple references
- list United States Patent Application No. 2004/0141977
- incorporate references by reference

